Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of PTH recombinant plasmid and PTH-rhMSC therapy for hypoparathyroidism
ChiCTR2100041719Phase 2Recruiting
- Sponsor
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Start
- Jan 2021
- Modality
- Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of PTH recombinant plasmid and PTH recombinant mesenchymal stem cells, sponsored by Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine. Started Jan 2021; status: recruiting.
02
Drugs
PTH recombinant plasmidPTH recombinant mesenchymal stem cells
Beyond the preview
Go deeper on ChiCTR2100041719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041719.